Posted the link today about MANF related to kidney diseases. Earlier the company PR'd MANF Therapeutics, Inc. received a notice of allowance from the US Patent & Trademark Office on MANF for beta cell disorders, including Type 1 and Type 2 diabetes.
Besides all the other indications MANF potentially has, you can start to see the connection on kidney disease which is huge. Diabetes of course is a massive opportunity as well, Maybe one day Amarantus will have a web page that references all the MANF research out there from all 4 corners of the globe.
Dr. Rubinfeld, who was one of the four original co-founders of Amgen has previously said:
"I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."
Do you remember when he said this?
It wasn't a year ago, it was FIVE years ago.
NOVEMBER 06, 2012
https://www.amarantus.com/news/press-releases...-dr-joseph
He was 79 at the time he said that and worked another 5 years moving it forward. I hope to be 64 one day and working on something I am passionate about let alone 84 like Dr. Rubinfeld.
How did he know MANF research over the last five years would pan out like he envisioned? I believe his experience gave him more insight into the potential of where this could go and kept him actively engaged for the next 5 years.
I also believe he knew 1000 x more than any of us arm chair BIO messageboard QB;s could know.
Here's another MANF link on kidney disease
Elevated urinary CRELD2 is associated with endoplasmic reticulum stress–mediated kidney disease
First published December 7, 2017
https://insight.jci.org/articles/view/92896
Dr. Joe passed away almost a year ago on Dec. 26, 2016. Glad to see the company moving forward in his memory.
Besides all the other indications MANF potentially has, you can start to see the connection on kidney disease which is huge. Diabetes of course is a massive opportunity as well, Maybe one day Amarantus will have a web page that references all the MANF research out there from all 4 corners of the globe.
Dr. Rubinfeld, who was one of the four original co-founders of Amgen has previously said:
"I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."
Do you remember when he said this?
It wasn't a year ago, it was FIVE years ago.
NOVEMBER 06, 2012
https://www.amarantus.com/news/press-releases...-dr-joseph
He was 79 at the time he said that and worked another 5 years moving it forward. I hope to be 64 one day and working on something I am passionate about let alone 84 like Dr. Rubinfeld.
How did he know MANF research over the last five years would pan out like he envisioned? I believe his experience gave him more insight into the potential of where this could go and kept him actively engaged for the next 5 years.
I also believe he knew 1000 x more than any of us arm chair BIO messageboard QB;s could know.
Here's another MANF link on kidney disease
Elevated urinary CRELD2 is associated with endoplasmic reticulum stress–mediated kidney disease
First published December 7, 2017
https://insight.jci.org/articles/view/92896
Dr. Joe passed away almost a year ago on Dec. 26, 2016. Glad to see the company moving forward in his memory.
12
